News

DMTC Exhibits Maritime Program Expertise at Indo Pacific 2023

DMTC Ltd will again have a presence at the upcoming Indo Pacific International Maritime Exposition in 2023. In the lead up to the Exposition, DMTC is releasing a series of snapshots showcasing the accomplishments of our Maritime Program over the past 15 years.

A not-for-profit company, DMTC is a trusted partner of Government within the Defence Innovation Ecosystem. With specialised expertise in managing multi-party collaborations, DMTC is integral to the de-risking and industrialisation of complex, asymmetric capabilities. The DMTC approach to innovation involves leading collaborations that bring together Government, industry and research partners to develop sovereign industrial capability and supporting technical expertise in areas aligned to the requirements of Defence and national security agencies.

Our services can be summarised into four key areas and are underpinned by our ISO9001 and ISO44001 accredited Project Management and Collaboration Framework. This allows DMTC to expedite delivery of capability into the hands of the warfighter.

To learn more about DMTC, we invite you to visit us at the DMTC pod located on the Defence Stand (1D11) on the Indo Pacific trade floor. Alternatively, request a meeting with us via this link.

Sovereign Capability at Scale

A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis.

Health Security Systems Australia (HSSA) is engaging with leading scientific experts from across Australia, led by Griffith University, including the Australian Rickettsial Reference Laboratory in Geelong, the NSW Department of Primary Industries, the University of Western Australia, and industry partner BioCina Pty Ltd, an Australian-based global biologics Contract Development Manufacturing Organisation (CDMO). (more…)

Pushing back against viruses with pandemic potential

Health Security Systems Australia (HSSA) is working with experts at the University of Melbourne at the Peter Doherty Institute for Infection and Immunity (Doherty Institute), The University of Queensland’s National Biologics Facility, and industry partner Biointelect Pty Ltd to develop a novel therapeutic platform technology to combat multiple viral pathogens with pandemic potential. (more…)

Key steps to advance vaccine manufacturing technology

Emerging Australian biotech company Sementis is engaging with Health Security Systems Australia and Australian universities to enhance the ability of its existing vaccine manufacturing technology to pivot, scale and rapidly deploy in response to emerging health and biosecurity challenges.

The initial 12-month collaboration with Sementis will draw on the company’s long-standing partnership with the University of South Australia as well as expert researchers from the Biomedicine Discovery Institute at Monash University and The Australian National University.

(more…)